Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 1216

Dr Andrea Gallamini - Centre Antoine Lacassagne, Nice, France

Dr Andrea Gallamini speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the 3 year update from the ECHELON-1 study into frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma.

He reports that the extended follow up beyond 3 years has shown a consistent advantage of brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A plus AVD) over doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

Dr Gallamini adds that the toxic profile of A plus AVD was acceptable with below 20% of patients continuing to show peripheral neuropathy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation